drugset / Trial / NCT01764945

Relative Bioavailability of BI 201335 Capsule Versus Three Different Oral Solutions

NCT01764945

Phase 1 Completed 56 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

The objective of the current study is to investigate the relative bioavailability of two different doses of BI 201335, administered as soft gelatine capsule in comparison to the equivalent doses of three different oral solution per dose of BI 201335.

Timeline

Start
2013-01
Primary completion
2013-03
Completion
2013-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Faldaprevir Small molecule Oral

Indications

No indication recorded.